MedPath

Examination of the effect of nasal irrigation in patients with cedar pollinosis

Active, not recruiting
Conditions
cedar pollinosis
Registration Number
jRCTs052220146
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Recruiting
Sex
All
Target Recruitment
45
Inclusion Criteria

1)Faculty members working at the University of Fukui Matsuoka Campus or students enrolled in the University of Fukui Faculty of Medicine 2)A person who can obtain written consent from the person 3)Those who have a positive antigen-specific IgE antibody test at the time of pre-registration test with cedar pollen 4)Those who develop allergic symptoms every year during the cedar pollen allergy season. 5)Those who comply with the compliance rules while participating in this research, undergo medical examinations and examinations specified in this research plan, and are able to report symptoms, etc.

Exclusion Criteria

1)People with a nasal irrigation rate of 80% or less 2)In the case of using therapeutic drugs for cedar pollinosis, those who started use, discontinued use, or changed the dosage during the period from 3 days prior to the start of the study to the end of the study. 3) Those who did not take the two tests after registration within the period 4)Persons who are judged by the investigator to be inappropriate for enrollment in this research

Study & Design

Study Type
Interventional
Study Design
single assignment
Primary Outcome Measures
NameTimeMethod
-

JRQLQ (Nasal symptom questionnaire)

Secondary Outcome Measures
NameTimeMethod
Blood allergy test

total IgE level, antigen-specific IgE level

Nasal discharge collection

determination of cedar-specific IgE antibodies, albumin, and short-chain fatty acids in nasal secretions, Proteins, peptide mixtures, metabolites of glycolytic systems, amino acids, organic acids, etc.

Nasal findings

edema of the nasal mucosa, color of the nasal mucosa, the degree of dryness of the nasal mucosa

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.